US 11,673,896 B2
Pyridine compounds as allosteric SHP2 inhibitors
Adrian Gill, Redwood City, CA (US); Naing Aay, Redwood City, CA (US); Kevin Mellem, Redwood City, CA (US); Andreas Buckl, Redwood City, CA (US); Elena S. Koltun, Redwood City, CA (US); Christopher Semko, Redwood City, CA (US); and Gert Kiss, Redwood City, CA (US)
Assigned to REVOLUTION MEDICINES, INC., Redwood City, CA (US)
Filed by Revolution Medicines, Inc., Redwood City, CA (US)
Filed on Jul. 22, 2019, as Appl. No. 16/518,796.
Application 16/518,796 is a continuation of application No. PCT/US2018/013018, filed on Jan. 9, 2018.
Claims priority of provisional application 62/449,529, filed on Jan. 23, 2017.
Prior Publication US 2020/0017517 A1, Jan. 16, 2020
Int. Cl. C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 491/107 (2006.01)
CPC C07D 491/107 (2013.01) [C07D 401/04 (2013.01); C07D 401/14 (2013.01)] 16 Claims
 
1. A compound of Formula I-Y1:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof, wherein:
A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl;
Y1 is —S— or a direct bond;
Y2 is —NRa; wherein the bond on the left side of Y2, as drawn, is bound to the pyridine ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3;
R1 is independently, at each occurrence, —H, —C1-C6alkyl, —OH, halogen, or —NH2;
R2 is —OH or —C1-C6alkyl;
R3 is combined with Ra to form a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more —C1-C6alkyl, —OH, —NH2, —CF3, —CHF2, or —CH2F;
R4 is —H, or —C1-C6alkyl, wherein each alkyl is optionally substituted with one or more —OH or halogen;
n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.